(1) Binder C (2) Cvetkovski F (3) Sellberg F (4) Berg S (5) Paternina Visbal H (6) Sachs DH (7) Berglund E (8) Berglund D

Frontiers in immunology | Free PMC Article

The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 expression is upregulated on memory T cells as well as activated T cells and plays an important role in activation of memory T cells despite the coexistence of several other costimulatory pathways. Anti-CD2 monoclonal antibodies have been shown to induce immune modulatory effects in vitro and clinical studies have proven the safety and efficacy of CD2-targeting biologics. Investigators have highlighted that the lack of attention to the CD2/LFA3 costimulatory pathway is a missed opportunity. Overall, CD2 is an attractive target for monoclonal antibodies intended for treatment of pathologies characterized by undesired T cell activation and offers an avenue to more selectively target memory T cells while favoring immune regulation.

Author Info: (1) Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden. Research and Development, ITB-Med AB, Stockholm, Sweden.

Author Info: (1) Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden. Research and Development, ITB-Med AB, Stockholm, Sweden. (2) Research and Development, ITB-Med AB, Stockholm, Sweden. (3) Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden. Research and Development, ITB-Med AB, Stockholm, Sweden. (4) Research and Development, ITB-Med AB, Stockholm, Sweden. (5) Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden. Research and Development, ITB-Med AB, Stockholm, Sweden. (6) Research and Development, ITB-Med AB, Stockholm, Sweden. Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, United States. (7) Research and Development, ITB-Med AB, Stockholm, Sweden. Division of Transplantation Surgery, CLINTEC, Karolinska Institute, and Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden. (8) Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden. Research and Development, ITB-Med AB, Stockholm, Sweden.

Citation: Front Immunol 2020 11:1090 Epub06/09/2020

Link to PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/32582179

Tags: